Achieving remission in generalized anxiety disorder what are the treatment options?

Psychiatric Times

Volumn 26, Issue 2, 2009, Pages 38-41

  Mandos, Laura A ^a   Reinhold, Jennifer A ^b   Rickels, Karl ^c  

^a UNIVERSITY OF THE SCIENCES   (United States)

^b Assistant Professor of Clinical Pharmacy ^*

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 62449131449     PISSN: 08932905     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Pollack MH, Endicott J, Liebowitz M, et al. Examining quality of life in patients with generalized anxiety disorder: clinical relevance and response to duloxetine treatment. J Psychiatr Res. 2008,42:1042-1049.
2. Allgulander C. Generalized anxiety disorder: what are we missing? Eur Neuropsychopharmacol. 2006;16(suppl2):S101-S108.
3. Rickels K, Rynn M. What is generalized anxiety disorder? J Clin Psychiatry. 2001;62(suppl 11):4-12.
4. Kessler RC, Keller MB, Wittchen HU. The epidemiology of generalized anxiety disorder. Psychiatr Clin North Am. 2001;24:19-39.
5. Rickels K, Schweizer E. The clinical course and long-term management of generalized anxiety disorder. J Clin Psychopharmacol. 1990;10(3 suppl): S101-S110.
6. Rickels K, Rynn M. Pharmacotherapy of generalized anxiety disorder. J Clin Psychiatry. 2002;63 (suppl 14):9-16.
7. Ormel J, VonKorff M, Ustun TB, et al. Common mental disorders and disability across cultures. Results from the WHO Collaborative Study on Psychological Problems in General Health Care. JAMA. 1994;272:1741-1748.
8. Schonfeld WH, Verboncoeur CJ, Fifer SK, et al. The functioning and well-being of patients with unrecognized anxiety disorders and major depressive disorder. J Affect Disord. 1997;43:105-119.
9. Spitzer RL, Kroenke K, Linzer M, et al. Health-related quality of life in primary care patients with mental disorders. Results from the PRIME-MD 1000 Study. JAMA. 1995;274:1511-1517.
10. Nutt DJ, Rickels K, Stein DJ. Generalized Anxiety Disorder: Symptomatology, Pathogenesis, and Management. London: Martin Dunitz Ltd; 2002.
11. Pollack MM, Kornstein SG, Spann ME, et al. Early improvement during duloxetine treatment of generalized anxiety disorder predicts response and remission at endpoint. J Psychiatr Res. 2008;42:1176-1184.
12. Bandelow B. Defining response and remission in anxiety disorders: toward an integrated approach. CNS Spectr. 2006;11 (suppl 12):21-28.
13. Rickels K, Rynn M, Iyengar M, Duff D. Remission of generalized anxiety disorder: a review of the paroxetine clinical trials database. J Clin Psychiatry. 2006;67:41-47.
14. Goodman WK. Selecting pharmacotherapy for generalized anxiety disorder. J Clin Psychiatry. 2004; 65(suppl 13):8-13.
15. Ballenger JC. Treatment of anxiety disorders to remission. J Clin Psychiatry. 2001;62(suppl 12):5-9.
16. Ballenger JC. Remission rates in patients with anxiety disorders treated with paroxetine. J Clin Psychiatry. 2004;65:1696-1707.
17. Bandelow B, Baldwin DS, Dolberg OT, et al. What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder? J Clin Psychiatry. 2006;67:1428-1434.
18. Ballenger JC. Overview of different pharmacotherapies for attaining remission in generalized anxiety disorder. J Clin Psychiatry. 2001;62(suppl 19):11-19.
19. Ballenger JC, Davidson JR, Lecrubier Y, et al. Consensus statement on generalized anxiety disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry. 2001;62(suppl 11):53-58.
20. Stahl SM. Don't ask, don't tell, but benzodiazepines are still the leading treatments for anxiety disorder. J Clin Psychiatry. 2002;63:9.
21. Rickels K, Downing R, Schweizer E, Hassman H. Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of im-ipramine, trazodone, and diazepam. Arch Gen Psychiatry. 1993;50:884-895.
22. Rickels K, Zaninelli R, McCafferty J, et al. Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study. Am J Psychiatry. 2003;160:749-756.
23. Zimmerman M, Postemak MA, Chelminski I. Is the cutoff to define remission on the Hamilton Rating Scale for Depression too high? J Nerv Ment Dis. 2005;193:170-175.
24. Rickels K, Garcia-Espana F, Mandos LA, Case GW. Physician Withdrawal Checklist (PWC-20). J Clin Psychopharmacol. 2008;28:447-451.
25. Rickels K, Amsterdam J, Clary C, et al. Buspirone in depressed outpatients: a controlled study. Psychopharmacol Bull. 1990;26:163-167.
26. Rickels K, Amsterdam J, Clary C, et al. Buspirone in major depression: a controlled study. J Clin Psychiatry. 1991;52:34-38.
27. Gammans RE, Stringfellow JC, Hvizdos AJ, et al. Use of buspirone in patients with generalized anxiety disorder and coexisting depressive symptoms. A meta-analysis of eight randomized, controlled studies. Neuropsychology. 1992;25:193-201.
28. Davidson JR, DuPont RL, Hedges D, Haskins JT. Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. J Clin Psychiatry. 1999;60:528-535.
29. Sramek JJ, Tansman M, Suri A, et al. Efficacy of buspirone in generalized anxiety disorder with coexisting mild depressive symptoms. J Clin Psychiatry. 1996;57:287-291.
30. Rynn MA, Brawman-Mintzer 0. Generalized anxiety disorder: acute and chronic treatment. CNS Spectr. 2004:9:716-723.
31. DeMartinis N, Rynn M, Rickels K, Mandos L. Prior benzodiazepine use and buspirone response in the treatment of generalized anxiety disorder. J Clin Psychiatry. 2000;61:91-94.
32. Baldwin DS, Anderson IM, Nutt DJ, et al. Evidence- based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2005;19:567-596.
33. Stocchi F, Nordera G, Jokinen RH, et al. Efficacy and tolerability of paroxetine for the long-term treatment of generalized anxiety disorder. J Clin Psychiatry. 2003;64:250-258.
34. Sher L. Prevention of the serotonin reuptake inhibitor discontinuation syndrome. Med Hypotheses. 2002;59:92-94.
35. Haddad PM. Antidepressant discontinuation syndromes. Drug Sat 2001;24:183-197.
36. Lader M. Pharmacotherapy of mood disorders and treatment discontinuation. Drugs. 2007;67:1657-1663.
37. Sheehan DV. Attaining remission in generalized anxiety disorder: venlafaxine extended release comparative data. J Clin Psychiatry. 2001;62(suppl 19): 26-31.
38. Allgulander C, Hirschfeld RM, Nutt DJ. Long-term treatment strategies in anxiety disorders. Psychopharmacol Bull. 2002;36(suppl 2):79-92.
39. Russell JM, Weisberg R, Fava M, et al. Efficacy of duloxetine in the treatment of generalized anxiety disorder in patients with clinically significant pain symptoms. Depress Anxiety. 2008;25:E1-E11.
40. Pollack MH, Meoni P, Otto MW, et al. Predictors of outcome following venlafaxine extended-release treatment of DSM-IV generalized anxiety disorder: a pooled analysis of short- and long-term studies. J Clin Psychopharmacol. 2003;23:250-259.
41. Endicott J, Russell JM, Raskin J, et al. Duloxetine treatment for role functioning improvement in generalized anxiety disorder: three independent studies. J Clin Psychiatry. 2007,68:518-524.
42. Covin R, Ouimet A, Seeds PM, Dozois DJ. A metaanalysis of CBT for pathological worry among clients with GAD. J Anxiety Disord. 2008;22:108-116.
43. Borkovec TD, Ruscio AM. Psychotherapy for generalized anxiety disorder. J Clin Psychiatry. 2001;62 (suppl 11):37-42.
44. Lang AJ. Treating generalized anxiety disorder with cognitive-behavioral therapy. J Clin Psychiatry. 2004;65(suppl13):14-19.
45. Gorman JM, Papp LA. Chronic anxiety: deciding the length of treatment. J Clin Psychiatry. 1990;(suppl 51):11-15.
46. Keller MB. The long-term clinical course of generalized anxiety disorder. J Clin Psychiatry. 2002;63 (suppl8):11-16.
47. Thase ME, Trivedi M. Optimizing treatment outcomes for patients with depression and generalized anxiety disorder. Psychopharmacol Bull. 2002;36(suppl 2):93-102.
48. Goddard AW, Brouette T, Almai A, et al. Early coadministration of clonazepam with sertraline for panic disorder. Arch Gen Pyschiatry. 2001;58:681-686.
49. Allgulander C, Sheehan DV. Generalized anxiety disorder: raising the expectations of treatment. Psychopharmacol Bull. 2002;36(suppl 2):68-78.